Nature Communications (Nov 2019)
Neratinib protects pancreatic beta cells in diabetes
- Amin Ardestani,
- Sijia Li,
- Karthika Annamalai,
- Blaz Lupse,
- Shirin Geravandi,
- Aleksandra Dobrowolski,
- Shan Yu,
- Siying Zhu,
- Tyler D. Baguley,
- Murali Surakattula,
- Janina Oetjen,
- Lena Hauberg-Lotte,
- Raquel Herranz,
- Sushil Awal,
- Delsi Altenhofen,
- Van Nguyen-Tran,
- Sean Joseph,
- Peter G. Schultz,
- Arnab K. Chatterjee,
- Nikki Rogers,
- Matthew S. Tremblay,
- Weijun Shen,
- Kathrin Maedler
Affiliations
- Amin Ardestani
- Centre for Biomolecular Interactions Bremen, University of Bremen
- Sijia Li
- Calibr at Scripps Research
- Karthika Annamalai
- Centre for Biomolecular Interactions Bremen, University of Bremen
- Blaz Lupse
- Centre for Biomolecular Interactions Bremen, University of Bremen
- Shirin Geravandi
- Centre for Biomolecular Interactions Bremen, University of Bremen
- Aleksandra Dobrowolski
- Centre for Biomolecular Interactions Bremen, University of Bremen
- Shan Yu
- Calibr at Scripps Research
- Siying Zhu
- Calibr at Scripps Research
- Tyler D. Baguley
- Calibr at Scripps Research
- Murali Surakattula
- Calibr at Scripps Research
- Janina Oetjen
- Centre for Biomolecular Interactions Bremen, University of Bremen
- Lena Hauberg-Lotte
- Center for Industrial Mathematics, University of Bremen
- Raquel Herranz
- Centre for Biomolecular Interactions Bremen, University of Bremen
- Sushil Awal
- Centre for Biomolecular Interactions Bremen, University of Bremen
- Delsi Altenhofen
- Centre for Biomolecular Interactions Bremen, University of Bremen
- Van Nguyen-Tran
- Calibr at Scripps Research
- Sean Joseph
- Calibr at Scripps Research
- Peter G. Schultz
- Calibr at Scripps Research
- Arnab K. Chatterjee
- Calibr at Scripps Research
- Nikki Rogers
- Calibr at Scripps Research
- Matthew S. Tremblay
- Calibr at Scripps Research
- Weijun Shen
- Calibr at Scripps Research
- Kathrin Maedler
- Centre for Biomolecular Interactions Bremen, University of Bremen
- DOI
- https://doi.org/10.1038/s41467-019-12880-5
- Journal volume & issue
-
Vol. 10,
no. 1
pp. 1 – 17
Abstract
Type 1 as well as type 2 diabetes are characterized by a loss of insulin-producing β-cells. Here the authors show that the FDA-approved drug neratinib has beneficial effects on β-cell survival, insulin secretion, and glycemic control in mouse models of diabetes.
